Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SPRY
stocks logo

SPRY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
26.25M
-69.68%
-0.437
-185.62%
25.33M
+217.63%
-0.482
+37.86%
40.83M
+159.75%
-0.395
-14.13%
Estimates Revision
The market is revising Upward the revenue expectations for ARS Pharmaceuticals, Inc. (SPRY) for FY2025, with the revenue forecasts being adjusted by 5.11% over the past three months. During the same period, the stock price has changed by -0.99%.
Revenue Estimates for FY2025
Revise Upward
up Image
+5.11%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.14%
In Past 3 Month
Stock Price
Go Down
down Image
-0.99%
In Past 3 Month
Wall Street analysts forecast SPRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRY is 30.00 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast SPRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRY is 30.00 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.970
sliders
Low
25.00
Averages
30.00
High
35.00
Current: 9.970
sliders
Low
25.00
Averages
30.00
High
35.00
Oppenheimer
Oppenheimer
Outperform
maintain
$40 -> $35
2025-11-11
Reason
Oppenheimer
Oppenheimer
Price Target
$40 -> $35
2025-11-11
maintain
Outperform
Reason
Oppenheimer lowered the firm's price target on ARS Pharmaceuticals to $35 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3 financials with $32.5M in revenue, beating consensus and surpassing OpCo estimates of $28.7M/$29.4M, respectively. Neffy's momentum reflects the DTC lift, back-to-school demand, and broader prescriber adoption across new epinephrine segments, with upcoming tailwinds from the virtual campaign, growing real-world evidence, and formulary adds in 2026, Oppenheimer adds.
Roth Capital
Kyle Bauser
initiated
$30
2025-11-04
Reason
Roth Capital
Kyle Bauser
Price Target
$30
2025-11-04
initiated
Reason
Roth Capital analyst Kyle Bauser resumed coverage of ARS Pharmaceuticals with a Buy rating and $30 price target. The firm is anticipating significant revenue growth from the rapid adoption of the company's signature product, neffy, which is an innovative intranasal epinephrine device for Type 1 allergic reactions, including anaphylaxis, the analyst tells investors in a research note. The ability of neffy to take significant share from outdated epinephrine auto-injectors is currently underappreciated, particularly given the recent sales growth to date, the firm added.
Roth Capital
NULL -> Buy
initiated
$40
2025-09-04
Reason
Roth Capital
Price Target
$40
2025-09-04
initiated
NULL -> Buy
Reason
Roth Capital initiated coverage of ARS Pharmaceuticals with a Buy rating and $40 price target.
Roth Capital
Jason Wittes
Buy
initiated
$40
2025-09-04
Reason
Roth Capital
Jason Wittes
Price Target
$40
2025-09-04
initiated
Buy
Reason
As previously reported, Roth Capital analyst Jason Wittes initiated coverage of ARS Pharmaceuticals with a Buy rating and $40 price target. The firm calls the company's neffy - the first needle-free way to administer epinephrine - a "vast improvement" over auto-injectors in terms of safety, dosing, and the form factor, and with 93% commercial payer coverage and a DTC campaign underway, it sees and "aggressive ramp" in sales leading to at least 60% share of the epinephrine market, the analyst tells investors in a research note. Roth further cites the company having a "$3B market opportunity" and upside from market expansion.
Scotiabank
Louise Chen
Buy
Initiates
$30
2025-03-07
Reason
Scotiabank
Louise Chen
Price Target
$30
2025-03-07
Initiates
Buy
Reason
Raymond James
Ryan Deschner
Strong Buy
Maintains
$26 → $28
2025-01-14
Reason
Raymond James
Ryan Deschner
Price Target
$26 → $28
2025-01-14
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for ARS Pharmaceuticals Inc (SPRY.O) is -6.63, compared to its 5-year average forward P/E of -11.54. For a more detailed relative valuation and DCF analysis to assess ARS Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.54
Current PE
-6.63
Overvalued PE
-7.08
Undervalued PE
-16.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.34
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.21
Undervalued EV/EBITDA
-4.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5911.42
Current PS
0.00
Overvalued PS
25675.06
Undervalued PS
-13852.22
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 326% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SPRY News & Events

Events Timeline

(ET)
2025-11-10
06:05:50
ARS Pharmaceuticals announces Q3 earnings per share of 52 cents, surpassing consensus estimate of 49 cents.
select
2025-11-04 (ET)
2025-11-04
08:25:00
ARS Pharmaceuticals Introduces 'Get Neffy on Us' Initiative
select
2025-10-08 (ET)
2025-10-08
08:02:25
ARS Pharmaceuticals Secures Positive Ruling from EPO Regarding Neffy
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-26Globenewswire
ARS Pharmaceuticals to Showcase neffy® at Piper Sandler Healthcare Conference
  • Conference Participation: ARS Pharmaceuticals will showcase its new product neffy® at the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, which is expected to attract investor interest in the company's innovative solutions for allergic reactions.
  • Executive Presentation: Co-Founder and CEO Richard Lowenthal, along with Chief Commercial Officer Eric Karas, will engage in a fireside chat on December 3 at 2:30 PM, highlighting the company's advancements in allergy treatment.
  • Investor Meetings: The management team will also hold one-on-one meetings with investors, aimed at strengthening relationships with potential investors and enhancing market confidence in ARS Pharmaceuticals.
  • Live Webcast: The fireside chat will be available via live webcast and archived on the company's website for 90 days, ensuring broader access to information and increasing the company's transparency and market engagement.
[object Object]
Preview
9.0
11-04Newsfilter
ARS Pharma to Showcase Real-World Data on Intranasal Epinephrine at the 2025 ACAAI Annual Scientific Meeting

  • Presentation Highlights: ARS Pharma will present a late-breaking oral presentation and six posters at the 2025 ACAAI Annual Scientific Meeting, focusing on the real-world effectiveness of their epinephrine nasal spray, neffy®.

  • Clinical Insights: The presentations will include case reports demonstrating the successful use of neffy® in treating anaphylaxis during food challenges and allergy immunotherapy, reinforcing its reliability compared to traditional injections.

  • Expert Endorsement: Dr. Jonathan Spergel emphasized that the data supports the effectiveness of intranasal epinephrine, providing confidence to clinicians and patients regarding its convenience and efficacy in emergency situations.

  • Company Commitment: ARS Pharma aims to empower patients at risk of severe allergic reactions by expanding research on neffy® and addressing the limitations associated with epinephrine auto-injectors, which often lead to delays in treatment.

[object Object]
Preview
9.0
11-03Newsfilter
ARS Pharma to Showcase Real-World Findings on Intranasal Epinephrine at the 2025 ACAAI Annual Scientific Meeting

  • Presentation Highlights: ARS Pharma will present a late-breaking oral presentation and six posters at the 2025 ACAAI Annual Scientific Meeting, showcasing the effectiveness of their epinephrine nasal spray, neffy®, in treating anaphylaxis.

  • Real-World Effectiveness: Data indicates that approximately 90% of patients treated with a single dose of neffy® for anaphylaxis experienced effective relief, reinforcing its reliability compared to traditional injection methods.

  • Clinical Insights: Case reports presented at the meeting demonstrate neffy®'s successful application in various clinical scenarios, including during food challenges and allergy immunotherapy, with rapid symptom improvement noted.

  • Company Commitment: ARS Pharma emphasizes the importance of their research and the convenience of needle-free administration of neffy®, aiming to enhance patient confidence and accessibility in emergency allergic reactions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ARS Pharmaceuticals Inc (SPRY) stock price today?

The current price of SPRY is 9.97 USD — it has increased 4.4 % in the last trading day.

arrow icon

What is ARS Pharmaceuticals Inc (SPRY)'s business?

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

arrow icon

What is the price predicton of SPRY Stock?

Wall Street analysts forecast SPRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRY is 30.00 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ARS Pharmaceuticals Inc (SPRY)'s revenue for the last quarter?

ARS Pharmaceuticals Inc revenue for the last quarter amounts to 32.50M USD, increased 1471.62 % YoY.

arrow icon

What is ARS Pharmaceuticals Inc (SPRY)'s earnings per share (EPS) for the last quarter?

ARS Pharmaceuticals Inc. EPS for the last quarter amounts to -0.52 USD, increased 160.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for ARS Pharmaceuticals Inc (SPRY)'s fundamentals?

The market is revising Upward the revenue expectations for ARS Pharmaceuticals, Inc. (SPRY) for FY2025, with the revenue forecasts being adjusted by 5.11% over the past three months. During the same period, the stock price has changed by -0.99%.
arrow icon

How many employees does ARS Pharmaceuticals Inc (SPRY). have?

ARS Pharmaceuticals Inc (SPRY) has 155 emplpoyees as of December 05 2025.

arrow icon

What is ARS Pharmaceuticals Inc (SPRY) market cap?

Today SPRY has the market capitalization of 985.52M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free